June 5 Company Quick Takes: Enzyvant's athymia candidate gets Priority review; plus Alnylam, Corbin and Institute Pasteur

Priority Review for Enzyvant's RVT-802
Enzyvant Sciences GmbH (Basel, Switzerland) said FDA accepted and granted Priority Review

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE